صاعد نازل
عضو مميز
- التسجيل
- 1 نوفمبر 2004
- المشاركات
- 8,096
شوف سهم phie
شوف جم مرتفع و شوف كمية و قيمة التداول !
و الله انى طايح عليه من كان سعره 22 بس لأن غير شرعى ما اخذت ولا اعلنت عنه ... و الله يعوضنا خير منه .
دورة المؤشرنت للتحليل الفني
50 دينار كويتي
BMCS يمكن يكون Bonu جديد !
- بادئ الموضوع صاعد نازل
- تاريخ البدء
شوف سهم phie
شوف جم مرتفع و شوف كمية و قيمة التداول !
و الله انى طايح عليه من كان سعره 22 بس لأن غير شرعى ما اخذت ولا اعلنت عنه ... و الله يعوضنا خير منه .
صاعد نازل
عضو مميز
- التسجيل
- 1 نوفمبر 2004
- المشاركات
- 8,096
ظروف السهمين متاشبهه
لأن كل السهمين عنده دواء لعلاج مرضى انفلوزا الخنازير و ينتظر السماح بالتسويق .
وسهمنا هذا دواءه فى ميزه ان يعالج مدمنى الكحول الذين يصابون فى هالمرض .. و ما اعلنوا عن ذلك الا لأن الادويه المتوفره لديها قصور فى علاج هاذى الفئه .
لأن كل السهمين عنده دواء لعلاج مرضى انفلوزا الخنازير و ينتظر السماح بالتسويق .
وسهمنا هذا دواءه فى ميزه ان يعالج مدمنى الكحول الذين يصابون فى هالمرض .. و ما اعلنوا عن ذلك الا لأن الادويه المتوفره لديها قصور فى علاج هاذى الفئه .
صاعد نازل
عضو مميز
- التسجيل
- 1 نوفمبر 2004
- المشاركات
- 8,096
انا اتفائل بأي سهم تداولاته قليله ويرتفع بسرعه
يا عينى عليك يا ابو سجى
واذا السهم نازل خبر فيه اظن راح يزيد التفاؤل .
البشاره
عضو نشط
والله التدوال ضعيف يجيب المرض ...
الشركة طالع عليها خبر اليوم واكيد اهو الي رفع سعرها بس ماأدري شنو معناته
BioTech Medics Retains Hogan & Hartson, LLP Law Firm for SHBAN(TM) Non-Alcohol Antiseptic Hand Sanitizer Solution Filings With FDA
Press Release
Source: BioTech Medics, Inc.
On Thursday September 17, 2009, 9:35 am EDT
Companies:BioTech Medics, Inc.
DALLAS, TX--(Marketwire - 09/17/09) - BioTech Medics, Inc. (Pinksheets:BMCS - News) announces that it has engaged the Washington, D.C. law firm of Hogan & Hartson, LLP to advise it, in conjunction with meeting any FDA requirements to market BioTech's multi-patented SHBAN(TM) Antiseptic Hand Sanitizer Solution Products.
BioTech has recently commenced independent clinical testing of SHBAN(TM) Hand Sanitizer Solution to determine if it reduces (or kills) the H1N1 (Swine) Influenza A virus.
In 2007 BioTech conducted an independent study in England to determine the efficacy of SHBAN against Avian H5N1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu). BioTech reported that the SHBAN Solution had clinically proven it had topically reduced (or killed) the Avian Influenza virus.
SHBAN is a bio-degradable product superior to most anti-bacterial hand sanitizers because 1) SHBAN is longer lasting, SHBAN does NOT contain alcohol gel which has poisoned over 22,000 children in the USA after application; 2) SHBAN is non-toxic when used as directed on humans; 3) SHBAN is non-staining; 4) SHBAN is non-flammable; and 5) SHBAN contains no ammonia, bleach, Benzalkonium Chloride (BOC), Triclosan� nor fragrance, or lotion ingredients. Most hand sanitizer products cannot make all of these claims.
SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and a patent pending for the US and international patent. SHBAN is a trademark of BioTech Medics, Inc. BioTech is seeking and negotiating USA and foreign distributorships at this time.
SHBAN(TM) in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against Staph. Aureus, Staph. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Prior research and clinical studies have been conducted at the University of TX Medical Branch, Galveston, TX; Microbiology & Biochemical Assay Laboratories - Houston, Texas; Pathology Associates, Pasadena, Texas; Texas A & M University - College of Veterinary Medicine, College Station, Texas; Baylor College of Dentistry, Dallas, TX; Allergan, Irvine, CA; Culleen Eye Institute, Baylor College of Medicine, Houston, Texas.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.
BioTech Medics Retains Hogan & Hartson, LLP Law Firm for SHBAN(TM) Non-Alcohol Antiseptic Hand Sanitizer Solution Filings With FDA
Press Release
Source: BioTech Medics, Inc.
On Thursday September 17, 2009, 9:35 am EDT
Companies:BioTech Medics, Inc.
DALLAS, TX--(Marketwire - 09/17/09) - BioTech Medics, Inc. (Pinksheets:BMCS - News) announces that it has engaged the Washington, D.C. law firm of Hogan & Hartson, LLP to advise it, in conjunction with meeting any FDA requirements to market BioTech's multi-patented SHBAN(TM) Antiseptic Hand Sanitizer Solution Products.
BioTech has recently commenced independent clinical testing of SHBAN(TM) Hand Sanitizer Solution to determine if it reduces (or kills) the H1N1 (Swine) Influenza A virus.
In 2007 BioTech conducted an independent study in England to determine the efficacy of SHBAN against Avian H5N1 Influenza NIBRG-14 Virus (also known as the Avian Bird Flu). BioTech reported that the SHBAN Solution had clinically proven it had topically reduced (or killed) the Avian Influenza virus.
SHBAN is a bio-degradable product superior to most anti-bacterial hand sanitizers because 1) SHBAN is longer lasting, SHBAN does NOT contain alcohol gel which has poisoned over 22,000 children in the USA after application; 2) SHBAN is non-toxic when used as directed on humans; 3) SHBAN is non-staining; 4) SHBAN is non-flammable; and 5) SHBAN contains no ammonia, bleach, Benzalkonium Chloride (BOC), Triclosan� nor fragrance, or lotion ingredients. Most hand sanitizer products cannot make all of these claims.
SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and a patent pending for the US and international patent. SHBAN is a trademark of BioTech Medics, Inc. BioTech is seeking and negotiating USA and foreign distributorships at this time.
SHBAN(TM) in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against Staph. Aureus, Staph. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Prior research and clinical studies have been conducted at the University of TX Medical Branch, Galveston, TX; Microbiology & Biochemical Assay Laboratories - Houston, Texas; Pathology Associates, Pasadena, Texas; Texas A & M University - College of Veterinary Medicine, College Station, Texas; Baylor College of Dentistry, Dallas, TX; Allergan, Irvine, CA; Culleen Eye Institute, Baylor College of Medicine, Houston, Texas.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.
دورة المؤشرنت للتحليل الفني
50 دينار كويتي